..a long term holder who doesn't read ann's or newsletters
Phosphagenics is developing two novel opioid products, a TPM®/Oxymorphone patch and a TPM®/Oxycodone patch. Today, both oxymorphone and oxycodone are
available as oral extended release (“ER”) medications for the treatment of moderate
to severe chronic pain in various global markets. Given the potential competitiveness
between the two molecules in the pain market, the Company has consciously formulated the two products using its TPM® drug delivery platform to treat two related
but distinct pain indications. The TPM®/Oxymorphone patch has been developed for
systemic delivery and treatment of moderate to severe chronic pain, while the TPM®/Oxycodone patch is for localised topical delivery and treatment of peripheral
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)